Small nucleolar RNA host gene 8: A rising star in the targets for cancer therapy

Xin Yuan1, Yuheng Yan1, Miaomiao Xue2

  • 1Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Insights

Small nucleolar RNA host gene 8 (SNHG8) acts as an oncogenic factor, upregulated in many cancers. This review details SNHG8's role in cancer progression and its clinical potential for diagnosis and treatment.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • Long non-coding RNAs (lncRNAs) are critical in cancer development.
  • Small nucleolar RNA host gene 8 (SNHG8) is an oncogenic lncRNA upregulated in various cancers.
  • SNHG8 belongs to the SNHG family, involved in processing small nucleolar RNAs.

Purpose of the Study:

  • To review the biological functions of SNHG8 in different cancer types.
  • To elucidate the mechanisms of SNHG8 interactions with microRNAs, mRNAs, and proteins.
  • To highlight the clinical significance of SNHG8 in cancer diagnosis, prognosis, and therapy.

Main Methods:

  • Literature review and synthesis of existing research on SNHG8.
  • Analysis of molecular mechanisms involving SNHG8.
  • Evaluation of clinical data related to SNHG8 expression and function.

Main Results:

  • SNHG8 is upregulated and functions as an oncogene in multiple cancer types.
  • SNHG8 influences cancer progression through interactions with miRNAs, mRNAs, and proteins.
  • Evidence suggests SNHG8's potential as a biomarker for cancer diagnosis and prognosis.

Conclusions:

  • SNHG8 plays a significant role in cancer pathogenesis and progression.
  • Understanding SNHG8 mechanisms can lead to novel therapeutic strategies.
  • SNHG8 holds promise for improving cancer clinical management.

Related Concept Videos

The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
9.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.7K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.5K